Study of encorafenib, binimetinib, cemiplimab, and fianlimab for melanoma with brain metastases
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial tests a combination of targeted drugs (encorafenib and binimetinib) followed by immunotherapy (cemiplimab and fianlimab) for people with advanced melanoma that has spread to the brain and is causing symptoms. The goal is to see if this approach can shrink tumors and help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced melanoma with a specific BRAF V600 mutation that has spread to the brain.
- You must have at least one brain tumor between 5 and 50 mm that is causing symptoms (like headache, seizures, or weakness).
- You must be able to swallow pills and have good overall health (ECOG performance status 0-2).
- You must have adequate kidney, liver, and blood cell counts (details checked by your doctor).
- You cannot have had prior targeted therapy for BRAF or MEK, or certain immunotherapies that included a drug called anti-LAG-3.
- You cannot have had brain radiotherapy before the trial, but you may get it later if needed under specific conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests two targeted medicines (binimetinib and encorafenib) for melanoma that has spread to the brain. It focuses on people whose tumor has a specific BRAF V600 mutation and who have brain metastases that are progressing or need treatment.
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
This trial studies how doctors use encorafenib plus binimetinib for real-world care in people with BRAF V600–mutated melanoma that can’t be removed by surgery or has spread. It may help improve understanding of which patients benefit and what happens in everyday clinical practice.
This trial tests a combination of two or three drugs (defactinib, avutometinib, with or without encorafenib) to shrink brain tumors that started from skin melanoma. It may be an option for people whose melanoma has a specific genetic change and who have already tried immunotherapy.
This early-phase study looks at whether people with melanoma can get the “right” follow-up (extra) treatment based on how well their cancer responds after starting targeted drugs before surgery. The goal is to improve outcomes while better matching treatment to each person’s tumor response.
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
Hear when a new Melanoma BRAF V600E/K Mutated trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.